We have analysed CCL20 levels in plasma and urine from patients with diabetic kidney disease (DKD, n = 98) and autosomal dominant polycystic kidney disease (ADPKD, n = 85) treated according to the guidelines and studied their association with baseline characteristics and long-term (median follow-up 4.9 and 7.1 years, respectively) clinical outcomes. Here, CCL20 is linked to autosomal dominant polycystic kidney disease.